Protagonist Therapeutics Inc (PTGX) is a biopharmaceutical company focused on discovering and developing peptide-based therapies for gastroenterology and rare diseases. Technical analysis plays a crucial role in assessing the stock's performance and potential future trends. By utilizing various technical indicators, investors can gain insights into PTGX's price movements and make informed decisions.

One of the commonly used technical indicators is the relative strength index (RSI), which measures the magnitude of recent price changes to determine overbought or oversold conditions. A high RSI value may indicate an overbought stock, while a low RSI may suggest an oversold stock. PTGX's stock RSI can provide valuable information about its current market sentiment.

Protagonist Therapeutics  (PTGX) Technical Analysis

Get insights into the technical analysis indicators of Protagonist Therapeutics Inc (PTGX) stock, including RSI, ADX, MACD, ROC, STOCHRSI, and WILLR. Discover key trends and patterns in the stock's performance without using verbs. Gain a deeper understanding of PTGX's technical analysis.

Protagonist Therapeutics Inc (PTGX) Technical Analysis: RSI, ADX, MACD, ROC, STOCHRSI, WILLR

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of erythrocytosis, iron overload, and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that is in Phase II clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist, which is in Phase II clinical trials for inflammatory bowel disease. The company has a license and collaboration agreement with Janssen Biotech, Inc. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.

Protagonist Therapeutics 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	58.44	Neutral	25.5%
auto_graphMACD	16.63	Neutral	85.6%
auto_graphCCI	47.21	Neutral	99.5%
auto_graphADX	30.74	Neutral	-
auto_graphATR	19.76	Buy	-
auto_graphWILLR	-44.84	Neutral	54.5%
auto_graphROC	27.85	Neutral	99.1%
auto_graphSTOCHRSI	32.23	Neutral	113.9%

Buy	1	-87.50%
Hold	7	-12.50%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

Protagonist Therapeutics (PTGX) Technical Analysis

Keep an eye on Protagonist Therapeutics

Frequently Asked Questions

What are the technical signals for Protagonist Therapeutics (PTGX) stock based on the last 30 days?

Take Your Investments to a Whole New Level